NO784096L - Framgangsmaate for diagnose av malignomer - Google Patents

Framgangsmaate for diagnose av malignomer

Info

Publication number: NO784096L
Authority: NO; Norway
Prior art keywords: test; stated; test method; solution; antigen
Prior art date: 1977-12-12

Application number

NO784096A

Other languages

English (en)

Norwegian (no)

Inventor

Friedrich Douwes

Original Assignee

R & Z Vermoegensverw Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-12-12

Filing date

1978-12-06

Publication date

1979-06-13

1978-12-06 Application filed by R & Z Vermoegensverw Gmbh filed Critical R & Z Vermoegensverw Gmbh

1979-06-13 Publication of NO784096L publication Critical patent/NO784096L/no

Links

238000000034 method Methods 0.000 title claims description 17
238000003745 diagnosis Methods 0.000 title claims description 5
238000012360 testing method Methods 0.000 claims description 46
239000000427 antigen Substances 0.000 claims description 38
102000036639 antigens Human genes 0.000 claims description 38
108091007433 antigens Proteins 0.000 claims description 38
210000000265 leukocyte Anatomy 0.000 claims description 34
206010028980 Neoplasm Diseases 0.000 claims description 30
239000000725 suspension Substances 0.000 claims description 25
230000005012 migration Effects 0.000 claims description 23
238000013508 migration Methods 0.000 claims description 23
108010074506 Transfer Factor Proteins 0.000 claims description 21
230000033001 locomotion Effects 0.000 claims description 19
210000004698 lymphocyte Anatomy 0.000 claims description 19
229920001817 Agar Polymers 0.000 claims description 17
239000008272 agar Substances 0.000 claims description 17
230000005764 inhibitory process Effects 0.000 claims description 15
238000010998 test method Methods 0.000 claims description 15
239000011521 glass Substances 0.000 claims description 9
210000000056 organ Anatomy 0.000 claims description 9
210000004369 blood Anatomy 0.000 claims description 8
239000008280 blood Substances 0.000 claims description 8
239000007788 liquid Substances 0.000 claims description 8
230000004899 motility Effects 0.000 claims description 8
230000008859 change Effects 0.000 claims description 7
239000000463 material Substances 0.000 claims description 7
238000000338 in vitro Methods 0.000 claims description 6
238000011534 incubation Methods 0.000 claims description 6
210000004881 tumor cell Anatomy 0.000 claims description 5
239000012503 blood component Substances 0.000 claims description 4
230000001413 cellular effect Effects 0.000 claims description 4
239000000284 extract Substances 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
235000015097 nutrients Nutrition 0.000 claims description 4
241000282412 Homo Species 0.000 claims description 2
230000015572 biosynthetic process Effects 0.000 claims description 2
230000007704 transition Effects 0.000 claims description 2
239000003125 aqueous solvent Substances 0.000 claims 1
230000036210 malignancy Effects 0.000 claims 1
239000000243 solution Substances 0.000 description 40
210000004027 cell Anatomy 0.000 description 27
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
201000011510 cancer Diseases 0.000 description 16
210000001519 tissue Anatomy 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
239000002609 medium Substances 0.000 description 11
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000012153 distilled water Substances 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
229920000936 Agarose Polymers 0.000 description 6
208000026310 Breast neoplasm Diseases 0.000 description 6
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 6
206010006187 Breast cancer Diseases 0.000 description 5
238000007792 addition Methods 0.000 description 5
239000000654 additive Substances 0.000 description 4
210000000601 blood cell Anatomy 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000008105 immune reaction Effects 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
239000000126 substance Substances 0.000 description 4
101000794475 Schistosoma mansoni Calcium-binding protein Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
210000003714 granulocyte Anatomy 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
238000010792 warming Methods 0.000 description 3
208000036632 Brain mass Diseases 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
206010070834 Sensitisation Diseases 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
230000007969 cellular immunity Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
230000006735 deficit Effects 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000004080 punching Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000008313 sensitization Effects 0.000 description 2
238000005728 strengthening Methods 0.000 description 2
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000007659 Fibroadenoma Diseases 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
238000009534 blood test Methods 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
201000003149 breast fibroadenoma Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000005684 electric field Effects 0.000 description 1
230000001712 encephalitogenic effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000011850 initial investigation Methods 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
208000025036 lymphosarcoma Diseases 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000002969 morbid Effects 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000036647 reaction Effects 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
239000013049 sediment Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011343 solid material Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000012085 test solution Substances 0.000 description 1
238000012549 training Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Physiology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Materials By Optical Means (AREA)
Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

NO784096A 1977-12-12 1978-12-06 Framgangsmaate for diagnose av malignomer NO784096L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE2755363A DE2755363C3 (de)	1977-12-12	1977-12-12	Testverfahren zur Diagnose von Malignomen

Publications (1)

Publication Number	Publication Date
NO784096L true NO784096L (no)	1979-06-13

Family

ID=6025947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO784096A NO784096L (no)	1977-12-12	1978-12-06	Framgangsmaate for diagnose av malignomer

Country Status (25)

Country	Link
JP (1)	JPS54100176A (fr)
AR (1)	AR220356A1 (fr)
AT (1)	AT360178B (fr)
AU (1)	AU4234978A (fr)
BE (1)	BE872651A (fr)
CA (1)	CA1129319A (fr)
CH (1)	CH646793A5 (fr)
DD (1)	DD139903A5 (fr)
DE (1)	DE2755363C3 (fr)
DK (1)	DK532678A (fr)
ES (2)	ES475905A1 (fr)
FI (1)	FI783782A7 (fr)
FR (1)	FR2411412A1 (fr)
GB (1)	GB2009927B (fr)
GR (1)	GR66576B (fr)
IL (1)	IL56152A0 (fr)
IT (1)	IT1160323B (fr)
LU (1)	LU80609A1 (fr)
NL (1)	NL7811903A (fr)
NO (1)	NO784096L (fr)
PL (1)	PL112675B1 (fr)
PT (1)	PT68891A (fr)
RO (1)	RO75333A (fr)
SE (1)	SE432157B (fr)
ZA (1)	ZA786908B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4436824A (en) *	1981-06-09	1984-03-13	Ortho Diagnostic Systems, Inc.	Leukocyte migration through antigen containing agaroses for immunocompetence testing
JPH0672158B2 (ja) *	1984-05-24	1994-09-14	チバ−ガイギ− アクチエンゲゼルシヤフト	精製されたヒトマクロファージ遊走阻止因子

1977
- 1977-12-12 DE DE2755363A patent/DE2755363C3/de not_active Expired
1978
- 1978-11-29 GR GR57767A patent/GR66576B/el unknown
- 1978-11-29 SE SE7812313A patent/SE432157B/sv unknown
- 1978-11-29 DK DK532678A patent/DK532678A/da unknown
- 1978-12-01 CH CH1232978A patent/CH646793A5/de not_active IP Right Cessation
- 1978-12-04 LU LU80609A patent/LU80609A1/de unknown
- 1978-12-06 AT AT872478A patent/AT360178B/de active
- 1978-12-06 NO NO784096A patent/NO784096L/no unknown
- 1978-12-06 NL NL7811903A patent/NL7811903A/xx not_active Application Discontinuation
- 1978-12-07 IL IL56152A patent/IL56152A0/xx unknown
- 1978-12-08 GB GB7847795A patent/GB2009927B/en not_active Expired
- 1978-12-08 DD DD78209631A patent/DD139903A5/de unknown
- 1978-12-08 AU AU42349/78A patent/AU4234978A/en active Pending
- 1978-12-08 FI FI783782A patent/FI783782A7/fi unknown
- 1978-12-09 RO RO7895854A patent/RO75333A/fr unknown
- 1978-12-11 ZA ZA00786908A patent/ZA786908B/xx unknown
- 1978-12-11 PT PT68891A patent/PT68891A/pt unknown
- 1978-12-11 FR FR7834749A patent/FR2411412A1/fr active Granted
- 1978-12-11 BE BE2057477A patent/BE872651A/xx not_active IP Right Cessation
- 1978-12-11 ES ES475905A patent/ES475905A1/es not_active Expired
- 1978-12-12 PL PL1978211672A patent/PL112675B1/pl unknown
- 1978-12-12 JP JP15459078A patent/JPS54100176A/ja active Pending
- 1978-12-12 AR AR274770A patent/AR220356A1/es active
- 1978-12-12 IT IT30722/78A patent/IT1160323B/it active
- 1978-12-12 CA CA317,809A patent/CA1129319A/fr not_active Expired
1979
- 1979-05-25 ES ES1979243564U patent/ES243564Y/es not_active Expired

Also Published As

Publication number	Publication date
RO75333A (fr)	1980-11-30
JPS54100176A (en)	1979-08-07
CH646793A5 (de)	1984-12-14
PL112675B1 (en)	1980-10-31
PT68891A (en)	1979-07-24
IT1160323B (it)	1987-03-11
ATA872478A (de)	1980-05-15
AT360178B (de)	1980-12-29
SE432157B (sv)	1984-03-19
FR2411412A1 (fr)	1979-07-06
NL7811903A (nl)	1979-06-14
ZA786908B (en)	1979-12-27
DE2755363A1 (de)	1979-06-13
CA1129319A (fr)	1982-08-10
DE2755363C3 (de)	1983-12-01
GB2009927B (en)	1982-10-06
SE7812313L (sv)	1979-06-13
FR2411412B3 (fr)	1981-03-27
GR66576B (fr)	1981-03-27
AR220356A1 (es)	1980-10-31
DK532678A (da)	1979-06-13
IT7830722A0 (it)	1978-12-12
BE872651A (nl)	1979-03-30
PL211672A1 (pl)	1979-09-10
AU4234978A (en)	1979-06-21
ES243564U (es)	1980-06-01
IL56152A0 (en)	1979-03-12
ES475905A1 (es)	1979-10-16
ES243564Y (es)	1980-12-16
DD139903A5 (de)	1980-01-23
GB2009927A (en)	1979-06-20
DE2755363B2 (de)	1979-12-20
LU80609A1 (de)	1979-05-16
FI783782A7 (fi)	1979-06-13

Publication	Publication Date	Title
Drexhage et al.	1979	A study of cells present in peripheral lymph of pigs with special reference to a type of cell resembling the Langerhans cell
Velican et al.	1976	Intimal thickening in developing coronary arteries and its relevance to atherosclerotic involvement
CN109350557A (zh)	2019-02-19	包含nadh和神经酰胺的抗衰老组合物、护肤品及其制备方法与应用
JP2025063161A (ja)	2025-04-15	ルテリアル、並びにその分離および培養方法
Mavligit et al.	1972	Multifaceted evaluation of human tumor immunity using a salt extracted colon carcinoma antigen
Contrepois	1995	Notes on the early history of infective endocarditis and the development of an experimental model
Rowen et al.	1985	Retinal pigment epithelial cells release a chemoattractant for astrocytes
Genner	1971	Verrucae vulgares. II. Demonstration of a complement fixation reaction
RU2140081C1 (ru)	1999-10-20	Способ отбора лекарственных препаратов для коррекции нарушений иммунного статуса при опухолевой болезни
NO784096L (no)	1979-06-13	Framgangsmaate for diagnose av malignomer
Crounse	1965	Keratin and the barrier: A human epidermal phospholipoprotein with water barrier properties
Mack et al.	1953	Preliminary electrophoretic analysis of human gastric juice
Kusel et al.	1984	The formation of surface membrane vesicles from schistosomula of Schistosoma mansoni
Sen Gupta et al.	1956	The liver in kala-azar
RU2256916C1 (ru)	2005-07-20	Способ дифференциальной диагностики туберкулеза и саркоидоза органов дыхания
RU2124730C1 (ru)	1999-01-10	Способ диагностики лепры
RU2050003C1 (ru)	1995-12-10	Способ диагностики трансформации кератоакантомы в плоскоклеточный рак кожи
Dudnyk	2021	Immunohistochemical diagnosis of the viability of the strangulation furrow
Colby-Germinario et al.	1977	Studies of cellular sensitization to myelin antigens in multiple sclerosis: Dissociation of MIF and LBT production in response to a peptide encephalitogenic in rhesus monkeys
RU2552314C2 (ru)	2015-06-10	Способ получения клеток и неклеточных элементов атеросклеротической бляшки
Tabor et al.	1981	The functional heterogeneity of murine-resident macrophages to a chemotactic signal and induction of C3b-receptor-mediated ingestion
SU1689856A1 (ru)	1991-11-07	Способ диагностики аутоиммунного поражени печени
Arzumanian et al.	2019	Antimicrobial activities of human biofluids and their antimicrobial peptide fractions against Candida albicans
RU2064680C1 (ru)	1996-07-27	Способ определения генерации супероксидного анион-радикала фагоцитами в биологическом материале
Butterworth et al.	1979	Immunological Studies on Schistosomes Cultured